Clinicians should be aware of the possibility of increased blood glucose-lowering efficacy of nateglinide if fluconazole and nateglinide are combined.
Read More »Issue 167 Item 12 FDA Soon To Approve New “Super Statin” Crestor (rosuvastatin)
The Introductiuon of Crestor will trigger another round of marketing wars and questions about which statin is best. Watch for a lot of claims. Find out the facts, which statin are best.
Read More »Issue 167 Item 13 U.S. Worried by Native Americans’ High Diabetes Rate
The number of preventable injury-related deaths remains disproportionately high for youth on reservations, due to diabetes reaching near epidemic levels among Native American adults, reported by the federal government last Thursday.
Read More »Issue 167 Item 14 Effect of Adding Exenatide (Synthetic Exendin-4) to Metformin
Exendin-4 is a promising therapeutic for patients with type 2 diabetes
Read More »Issue 167 Item 15 Results From Low–Glycemic Index Diets in the Management of Dia
Choosing low-GI foods in place of conventional or high-GI foods has a small but clinically useful effect on medium-term glycemic control in patients with diabetes.
Read More »Issue 166 Item 1 Possible New Treatment for Type 1 Diabetes
Researchers successful in reversing type 1 diabetes by “teaching” the newly emerging immune cells not to attack the insulin-secreting islet cells.
Read More »Issue 166 Item 2 Quantity Not Quality of Food, Linked to Obesity
New survey links food portions to the growing epidemic of obesity in this county and abroad.
Read More »Issue 166 item 3 LANDMARK STUDY FINDS ADULTS FAIL TO GET RECOMMENDED CARE
The largest and most comprehensive examination of health care quality in the US finds people with diabetes received only 45 percent of the care they need.
Read More »Issue 166 item 4 Glimepiride (Amaryl®) Provides Glycemic Control and Weight Loss
Once daily glimepiride dosages provide effective glycemic control and result in weight neutralizing or reducing effects in patients with Type 2 diabetes.
Read More »Acarbose Cuts Risk of Hypertension and CVD For Patients with Im
First prospective intervention study testing the postprandial hyperglycemia hypotheses as a risk factor for cardiovascular disease. “Acarbose treatment was associated with a relative risk reduction of 49% for cardiovascular events.
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.